FDA OKs Neoadjuvant/Adjuvant Pembrolizumab in NSCLC FDA OKs Neoadjuvant/Adjuvant Pembrolizumab in NSCLC
The approval allows for continuous immunotherapy treatment around surgery for resectable non-small cell lung cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Immunotherapy | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer